冠状动脉旁路移植术后静脉桥再狭窄的基因治疗研究进展  

Advance in the research of gene therapy for restenosis of saphenous vein grafts after coronary artery bypass grafting

作　　者：郑辉[1] 薛松[1] 

机构地区：[1]上海交通大学医学院附属仁济医院心胸外科,200127

出　　处：《国际遗传学杂志》2010年第6期364-368,共5页International Journal of Genetics

基　　金：上海市科委基金（08411964100）

摘　　要：冠状动脉旁路移植术是治疗缺血性心脏病安全、有效的方法.自体大隐静脉是术中最常用的移植血管材料.但是血栓形成、内膜增厚和粥样硬化导致的静脉桥再狭窄严重影响了其通畅率,而且至今尚无有效的治疗药物.分子生物学技术理论的发展为冠状动脉旁路移植术后静脉桥再狭窄的防治提供了新思路,基因治疗静脉桥再狭窄已成为目前研究的热点.本文主要从静脉桥再狭窄防治的目的基因、基因导入方式、基因载体等方面,对静脉桥再狭窄基因治疗的研究进展进行综述.Coronary artery bypass grafting（CABG） is a safe and highly effective method for treatment of ischemic heart disease. The autologous saphenous vein grafts are the most common types of conduits used in CABG. But the restenosis of vein grafts which result from thrombosis, neointimal hyperplasia and atherosclerosis has severely affected the venous grafts patency, and effective pharmacological interventions for vein grafts failure have not emerged. The advances in molecular biology offers novel approaches for the management of vein graft restenosis, and gene therapy is the hot spot currently. This article reviews the progress in gene therapy for vein grafts restenosis, regarding therapeutic target gene, methods of gene delivery and gene vector.

关 键 词：冠状动脉旁路移植术 静脉桥 再狭窄 基因载体 

分 类 号：R654.2[医药卫生—外科学]